Park et al. [21] investigated prognostic value of COX-2 for cancers with and without ER expression and did not find evidence of decreased survival while similar studies of other authors lead to a conclusion that increased COX-2 expression is associated with a worse survival of patients with ER-negative breast cancers [7, 15]. This evidence concerns the gene PTGS2 and cancer.